Clinical Summary
Clinical Summary: Impact of Vagus Nerve Stimulation on Suicidal Ideation in Markedly Treatment-Resistant Major Depression: A RECOVER Study Report
Patients with markedly treatment-resistant major depression often carry persistent suicidal ideation, yet few treatments have demonstrated specific antisuicidal effects. This study addresses a practical question for clinicians using vagus nerve stimulation: whether adjunctive VNS changes suicidal ideation over time in a chronically ill, high-risk TRD population.
Design
multicenter, randomized, triple-blind, sham-controlled, 12-month design
N
The analytic sample (N = 463)
Population
participants with markedly TRD
Duration
12-month design
Key Findings
- Among participants with meaningful baseline SI (CSI score ≥3), active VNS was associated with more time in clinically meaningful improvement in SI across the 10-month observation period than sham VNS (OR = 1.43; 95% CI, 1.004–2.021; P = .047).
- Among participants with meaningful baseline SI, active VNS was associated with significantly more months in SI remission than sham VNS during months 10–12 (OR = 1.67; 95% CI, 1.007–2.763; P = .047).
- For remission across the full 12 months in participants with meaningful baseline SI, active and sham VNS did not differ significantly (OR = 1.38; 95% CI, 0.954–1.981; P = .087).
- By month 12 in participants with meaningful baseline SI, the mean (SD) drop in CSI score was 2.42 (0.19) for the active VNS group and 2.12 (0.19) for the sham VNS group; the visit effect across both treatments was significant (P<.001), while the treatment group effect showed a trend (P = .091).
- Among participants without clinically meaningful SI at baseline, emergence of meaningful SI during the 12-month study period was infrequent and did not differ between treatment arms (OR = 1.24; 95% CI, 0.49–3.11; P = .650).
Clinical Bottom Line
For markedly treatment-resistant major depression with baseline clinically meaningful suicidal ideation, adjunctive active VNS improved the likelihood of sustained suicidal ideation improvement versus sham, with the clearest remission advantage emerging in months 10–12. VNS was not associated with increased suicidal ideation in patients with or without baseline ideation.
Practice Implications
- Do not frame VNS as an acute antisuicidal intervention; benefits in suicidal ideation accumulated over time, with the strongest remission signal in months 10–12.
- In patients with markedly TRD and baseline clinically meaningful SI, consider VNS as a longer-term adjunctive option when persistent ideation remains despite multiple prior treatment failures.
- Continue structured monitoring of suicidal ideation during VNS treatment, since the study tracked change using repeated measurements across months 3–12 rather than relying on single time points.
- These findings apply best to chronic SI in markedly treatment-resistant unipolar depression, not to patients with severe suicidal intent/behavior at baseline, who were excluded from RECOVER.
